Development of indazole mineralocorticoid receptor antagonists and investigation into their selective late-stage functionalization.

导出原文传递

翻译打印收藏纠错

作者： Kun,Liu ^[1] ; Ravi,Kurukulasuriya ^[1] ; Kevin,Dykstra ^[1] ; Lisa,DiMichelle ^[1] ; Jinchu,Liu ^[1] ; Petr,Vachal ^[1] ; Anthony,Ogawa ^[1] ; Robert J,DeVita ^[1] ; Dong-Ming,Shen ^[1] ; Qiang,Tan ^[1] ; Yili,Chen ^[1] ; Don,Gauthier ^[1] ; Andreas,Verras ^[1] ; Alejandro,Crespo ^[1] ; Beata,Zamlynny ^[1] ; Jeffrey,Madwed ^[1] ; Maarten,Hoek ^[1] ; Thomas,Bateman ^[1] ; Yun-Fang,Yang ^[2] ; K N,Houk ^[2] ; Shane,Krska ^[1] ; Tim,Cernak ^[3]

作者单位： Merck & Co., Inc., Rahway, NJ 07065, United States. ^[1] University of California at Los Angeles, Department of Chemistry and Biochemistry, Los Angeles, CA 90095, United States. ^[2] Merck & Co., Inc., Rahway, NJ 07065, United States. Electronic address: tcernak@med.umich.edu. ^[3]

关键词 CH borylation CH functionalization High-throughput experimentation Late-stage functionalization Mineralocorticoid receptor antagonists

主题词吲唑类(Indazoles);分子结构(Molecular Structure)

DOI 10.1016/j.bmcl.2019.04.024

PMID 31104995

发布时间 2020-09-09

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交